Search This Blog

Friday, January 4, 2019

Nightstar Therapeutics initiated at UBS


Nightstar Therapeutics initiated with a Buy at UBS. UBS analyst Carter Gould initiated Nightstar Therapeutics with a Buy rating and $21 price target.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)